8-K: Niagen Bioscience Soars on Q2 Earnings, Boosts Outlook

Niagen Bioscience, Inc. reported strong second-quarter 2025 financial results, with net sales up 37% and net income reaching $3.6 million, leading to an increased full-year revenue outlook.

Summary

• Total net sales for Q2 2025 increased 37% year-over-year to $31.1 million.
• Tru Niagen sales reached $22.7 million, growing 22% year-over-year.
• Niagen ingredient sales increased 135% year-over-year to $7.4 million, including food-grade and pharmaceutical-grade.
• Gross margin improved by 480 basis points to 65.0%.
• Net income was $3.6 million, or $0.05 earnings per share, up from breakeven in the prior year quarter.
• Adjusted EBITDA, a non-GAAP measure, increased 221% to $5.0 million.
• Total cash provided by operations was $9.1 million during the six months ended June 30, 2025.
• The company ended the quarter with $60.5 million in cash and no debt.
• Full year 2025 revenue outlook was raised to 22%-27% year-over-year growth, up from the previous 20%-25%.
• A peer-reviewed clinical study of Niagen in individuals with Werner syndrome was published in Aging Cell on June 9, 2025.
• An exclusive worldwide license agreement was entered into with Haukeland University Hospital on July 8, 2025, for developing Niagen as a potential pharmaceutical therapy for Parkinson's disease.
• Patient dosing for the Phase III NOPARK trial, the largest clinical study of NAD+ augmentation in early Parkinson's disease, was completed in June 2025, with data analysis underway and publication expected in 2026.
• Tru Niagen was launched as an exclusive in-room amenity and Niagen IV introduced at The Spa by Equinox Hotel New York on July 14, 2025.
• As of August 2025, Niagen Plus products are available in over 800 leading wellness clinics in the U.S., up from more than 475 clinics in December 2024.

Sentiment

Score: 9

Explanation: The company reported exceptionally strong financial results across all key metrics, including significant revenue growth, a shift to profitability, and robust cash generation. The increased full-year outlook and strategic advancements in clinical development and market expansion indicate strong positive momentum and future potential, despite some expected normalization in gross margins and increased G&A expenses.

Positives

• Total net sales increased significantly by 37% to $31.1 million in Q2 2025.
• Tru Niagen sales grew by 22% to $22.7 million, demonstrating strong consumer product performance.
• Niagen ingredient sales surged by 135% to $7.4 million, indicating robust demand for raw materials.
• Gross margin improved substantially by 480 basis points to 65.0%, reflecting better product and business mix and cost efficiencies.
• Achieved net income of $3.6 million ($0.05 EPS) in Q2 2025, a significant turnaround from breakeven in the prior year.
• Adjusted EBITDA increased by 221% to $5.0 million, highlighting strong operational profitability.
• Generated $9.1 million in cash from operations during the first six months of 2025, indicating strong cash flow generation.
• Ended the quarter with a healthy cash balance of $60.5 million and no debt.
• Increased the full year 2025 revenue growth outlook to 22%-27% (from 20%-25%), signaling confidence in continued market expansion.
• Sales and marketing expense as a percentage of net sales improved by 420 basis points to 26.4%, reflecting enhanced marketing efficiency.
• Published a peer-reviewed clinical study of Niagen in Werner syndrome, validating its scientific basis.
• Secured a worldwide exclusive license agreement for Parkinson's disease therapy, expanding into regulated pharmaceutical applications.
• Completed patient dosing for the Phase III NOPARK trial, a major milestone in Parkinson's disease research.
• Expanded market reach by launching Tru Niagen and Niagen IV in luxury hospitality (Equinox Hotel New York).
• Significantly increased the number of wellness clinics offering Niagen Plus products to over 800, up from 475 in December 2024.

Negatives

• Gross margin improvements in Q2 2025 were partially due to temporary factors like lower-cost inventory purchases and are expected to normalize in future periods.
• General and administrative expenses increased by 28% ($1.6 million) due to higher employee-related expenses, share-based compensation, and professional/consulting fees.
• The absence of a $3.5 million royalty expense reversal that occurred in 2024 will contribute to higher general and administrative expenses in 2025.

Risks

• Inflationary conditions and adverse economic conditions could impact business operations and consumer spending.
• The company has a history of operating losses, and while currently profitable, future profitability is not guaranteed.
• Ability to maintain and grow sales, marketing, and distribution capabilities is crucial for continued success.
• Changing consumer perceptions of the company's products could negatively affect sales.
• Reliance on a single or limited number of third-party suppliers poses supply chain risks.
• Conducting business in China involves specific risks, including unanticipated developments.
• Ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner is essential for growth in that segment.
• Ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities is critical for pharmaceutical-grade Niagen distribution.
• Ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list is necessary for certain product offerings.
• Ability to maintain and enforce existing intellectual property and obtain new patents is vital for competitive advantage.
• Whether the potential benefits of Nicotinamide Riboside Chloride (NRC) can be further supported by ongoing research.
• Further research and development and the results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development.
• Ability to enroll sufficient numbers of subjects in clinical trials could impact research timelines.
• Determinations made by the FDA and other governmental authorities could affect product approvals and market access.
• Economic and market instability, including as a result of tariffs or trade conflicts, could adversely impact financial performance.

Future Outlook

Niagen Bioscience is revising its full-year 2025 revenue growth expectation to 22%-27% year-over-year, up from the previous 20%-25%, reflecting anticipated continued expansion of its e-commerce business and growth through new and established partnerships. Gross margin is expected to improve slightly year-over-year compared to 61.8% in 2024, driven by supply chain optimization and cost savings. Sales and marketing expenses are projected to increase in absolute dollars but decrease as a percentage of net sales, reflecting enhanced efficiencies. Research and development spending is expected to align closely with 2024 levels ($6.0 million), while general and administrative expenses are anticipated to increase by $7.0-$8.0 million due to share-based compensation, growth investments, and the absence of a 2024 royalty expense reversal.

Management Comments

• "We delivered an excellent second quarter, with $31.1 million in net sales, up 37% year-over-year, and $3.6 million in net income." Rob Fried, CEO
• "As the pioneers of this blossoming NAD+ market, we continue to invest in the future while maintaining our focus on profitable growth." Rob Fried, CEO

Industry Context

Niagen Bioscience operates within the expanding NAD+ market, a segment of the healthy aging and nutraceutical industry focused on cellular metabolism and longevity. The company's strong growth in both consumer (Tru Niagen) and ingredient sales, coupled with strategic clinical advancements in areas like Parkinson's disease and Werner syndrome, positions it as a leader. Its expansion into luxury hospitality and wellness clinics reflects a broader trend of integrating science-backed supplements into premium health services, differentiating it from general supplement providers by focusing on clinically validated ingredients and regulated therapeutic applications.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.
• The company's focus on peer-reviewed clinical studies (e.g., Werner syndrome, NOPARK trial for Parkinson's disease) and securing exclusive pharmaceutical development rights (Haukeland University Hospital) suggests a strategy aimed at higher scientific validation and regulated market entry, which is a differentiating factor in the broader dietary supplement industry often characterized by less rigorous clinical evidence.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased profitability, raised outlook, and strategic advancements in product development and market expansion, potentially leading to increased share value.
• Employees: Higher employee-related expenses and increased R&D investments suggest continued investment in human capital.
• Customers: Expansion of Tru Niagen availability (e-commerce, Equinox Hotel, wellness clinics) indicates improved access to products.
• Suppliers: Increased inventory purchases and scaling of inventory reserves suggest higher demand for raw materials.
• Creditors: Strong cash position ($60.5 million) and no debt indicate a healthy financial standing, reducing credit risk.

Next Steps

• Data analysis is underway for the Phase III NOPARK trial.
• Publication of data from the Phase III NOPARK trial is expected in 2026.
• Continued strategic investments to enhance and strengthen brand awareness and support various business channels.
• Maintaining steady investments in research and development throughout 2025.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in Q2 2025, with significant revenue growth, a strong return to profitability, and robust cash generation. The upward revision of the full-year revenue outlook signals continued confidence in market expansion and operational efficiency. Strategic advancements in clinical research (Parkinson's, Werner syndrome) and market penetration (wellness clinics, luxury hospitality) underscore a strong growth trajectory and potential for future regulated therapeutic applications. While some gross margin normalization is expected, the overall financial health and strategic positioning warrant a strong buy recommendation for investors seeking exposure to the growing healthy aging and NAD+ market.

Keywords

Niagen Bioscience, NAGE, NAD+, Nicotinamide Riboside, Tru Niagen, Bioscience, Healthy Aging, Dietary Supplements, Pharmaceuticals, Parkinson's Disease, Werner Syndrome, Clinical Trials, Biotechnology, Nutraceuticals, Health & Wellness